Pfizer Philippines Accused Of Bribery For Offering 5 Million Discount Cards
This article was originally published in PharmAsia News
Executive Summary
The head of the Philippines Senate accused Pfizer Philippines of attempting to bribe the government to circumvent the nation's new drug-pricing law. The allegation is an interpretation of Pfizer's offer to provide 5 million discount cards to the Department of Health, mainly for the company's Norvasc (amlodipine) for treating hypertension. The head of the Pharmaceutical and Healthcare Association of the Philippines revealed the offer, which he said was made before the department set maximum retail prices for 22 drugs. The department rejected the company's offer, but the Senate president said it was an attempt to bribe the government into blocking enforcement of the Quality Affordable Medicine Law. (Click here for more
You may also be interested in...
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.